RxDoctor Payments Data

Emily Wittig, PA

Geriatric Medicine · Plymouth Meeting, PANPI 1083345896

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Acadia Pharmaceuticals Inc at 36.9% of the total.

$733in general payments, 2019–2025

Across 14 payments — averaging $52.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$270
  • Teva Pharmaceuticals USA, Inc.$166
  • Amneal Pharmaceuticals LLC$117
  • UCB, Inc.$50
  • Otsuka America Pharmaceutical, Inc.$47
  • Pfizer$38
  • plus $44 from 2 others

What the payments were for

  • Food & beverage$733100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$733 in reported general payments places this provider in the 75th percentile of 217 geriatric medicine providers in Pennsylvania.

See all geriatric medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$192,058
Medicare patients
339
Services billed
2,055

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OdefseyEmtricitab/Rilpiviri/Tenof Ala12$45,692
EliquisApixaban91$39,229
JardianceEmpagliflozin52$18,104
ViberziEluxadoline13$11,231
RestasisCyclosporine12$9,025
MyrbetriqMirabegron27$6,217
JanuviaSitagliptin Phosphate17$4,739
Divalproex Sodium68$4,653
Doxepin Hcl36$4,531
Atorvastatin Calcium241$3,427
Ezetimibe37$2,911
Amlodipine Besylate273$2,593
Insulin Lispro Kwikpen U-100Insulin Lispro17$2,535
AlogliptinAlogliptin Benzoate14$2,481
Pantoprazole Sodium112$2,395

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$38$39,22991 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$117$2,228178 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 217 geriatric medicine providers in Pennsylvania.

Other geriatric medicine in Plymouth Meeting

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →